Log in to save to my catalogue

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inh...

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inh...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_34d487ab4e35409d91ce088f409d4cf7

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

About this item

Full title

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Publisher

London: Nature Publishing Group UK

Journal title

EMBO molecular medicine, 2015-08, Vol.7 (8), p.1063-1076

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer‐related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pancreaticoduodenectomy offers patients the possibility of a cure, but most will die of recurrent or metastatic d...

Alternative Titles

Full title

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_34d487ab4e35409d91ce088f409d4cf7

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_34d487ab4e35409d91ce088f409d4cf7

Other Identifiers

ISSN

1757-4676

E-ISSN

1757-4684

DOI

10.15252/emmm.201404827

How to access this item